Bristol-Myers Squibb, one of the world's largest drugmakers, will team up with a Dutch biotechnology company whose first approved drug could cost more than $1 million.
GlaxoSmithKline has lifted its stake in the group's Indian subsidiary to 75 percent, the British drugmaker said on Monday.
(HealthDay)—The current system of Graduate Medical Education (GME) funding is not adequate in funding urology residency programs and may lead to a significant shortage of urologists in the United States, ...
British drugmaker GlaxoSmithKline said it intends to increase its holdings in its Indian and Nigerian divisions, as part of a long-term strategy to expand into emerging markets, in a statement on Monday.
One of Singapore's two investment funds said Thursday it had paid $100 million for a minority stake in an Indian medical group, as part of its plan to shifts focus to emerging markets.